Cantillon Capital Management LLC decreased its position in shares of Becton Dickinson and Co (NYSE:BDX) by 6.2% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,042,413 shares of the medical instruments supplier’s stock after selling 68,907 shares during the quarter. Becton Dickinson and accounts for approximately 3.1% of Cantillon Capital Management LLC’s investment portfolio, making the stock its 15th largest holding. Cantillon Capital Management LLC owned 0.39% of Becton Dickinson and worth $272,070,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in BDX. Acropolis Investment Management LLC acquired a new stake in shares of Becton Dickinson and during the third quarter worth about $101,000. Almanack Investment Partners LLC. acquired a new stake in shares of Becton Dickinson and during the second quarter worth about $105,000. Truvestments Capital LLC acquired a new stake in shares of Becton Dickinson and during the third quarter worth about $105,000. Bartlett & Co. LLC lifted its holdings in shares of Becton Dickinson and by 2,900.0% during the second quarter. Bartlett & Co. LLC now owns 450 shares of the medical instruments supplier’s stock worth $108,000 after purchasing an additional 435 shares during the period. Finally, Bridgeworth LLC acquired a new stake in shares of Becton Dickinson and during the second quarter worth about $131,000. 86.25% of the stock is owned by hedge funds and other institutional investors.

Shares of NYSE:BDX opened at $246.07 on Monday. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.23 and a quick ratio of 0.81. The company has a market capitalization of $65.84 billion, a price-to-earnings ratio of 22.43, a P/E/G ratio of 1.69 and a beta of 1.19. Becton Dickinson and Co has a 12-month low of $209.91 and a 12-month high of $265.87.

Becton Dickinson and (NYSE:BDX) last announced its earnings results on Tuesday, November 6th. The medical instruments supplier reported $2.93 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $2.93. The business had revenue of $4.40 billion during the quarter, compared to the consensus estimate of $4.36 billion. Becton Dickinson and had a return on equity of 13.84% and a net margin of 1.47%. The business’s quarterly revenue was up 39.0% on a year-over-year basis. During the same period in the prior year, the company posted $2.40 EPS. On average, sell-side analysts anticipate that Becton Dickinson and Co will post 12.15 EPS for the current year.

A number of research analysts have issued reports on the company. Citigroup decreased their price target on Becton Dickinson and from $289.00 to $279.00 and set a “buy” rating for the company in a report on Tuesday, November 13th. Piper Jaffray Companies decreased their price target on Becton Dickinson and to $250.00 and set an “overweight” rating for the company in a report on Tuesday, November 6th. Barclays set a $260.00 price target on Becton Dickinson and and gave the company a “hold” rating in a report on Thursday, November 8th. Wells Fargo & Co decreased their price target on Becton Dickinson and from $290.00 to $280.00 and set an “outperform” rating for the company in a report on Wednesday, November 7th. Finally, KeyCorp boosted their price target on Becton Dickinson and from $264.00 to $273.00 and gave the company an “overweight” rating in a report on Thursday, November 8th. Five research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Becton Dickinson and currently has a consensus rating of “Buy” and a consensus target price of $253.79.

In other news, SVP Charles R. Bodner sold 2,080 shares of the company’s stock in a transaction that occurred on Friday, November 16th. The stock was sold at an average price of $245.83, for a total transaction of $511,326.40. Following the completion of the transaction, the senior vice president now directly owns 4,497 shares of the company’s stock, valued at approximately $1,105,497.51. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Ribo Alberto Mas sold 4,530 shares of the company’s stock in a transaction that occurred on Wednesday, November 14th. The stock was sold at an average price of $237.01, for a total value of $1,073,655.30. Following the transaction, the executive vice president now directly owns 14,596 shares of the company’s stock, valued at $3,459,397.96. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 70,665 shares of company stock valued at $16,807,058. Corporate insiders own 1.00% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Cantillon Capital Management LLC Decreases Position in Becton Dickinson and Co (BDX)” was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.dailypolitical.com/2018/11/19/cantillon-capital-management-llc-decreases-position-in-becton-dickinson-and-co-bdx.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Featured Story: How to Invest in Marijuana Stocks

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.